W. Tad Archambault

750 total citations
16 papers, 523 citations indexed

About

W. Tad Archambault is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, W. Tad Archambault has authored 16 papers receiving a total of 523 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cardiology and Cardiovascular Medicine, 4 papers in Epidemiology and 3 papers in Infectious Diseases. Recurrent topics in W. Tad Archambault's work include Cardiovascular Function and Risk Factors (5 papers), Heart Failure Treatment and Management (4 papers) and Viral Infections and Outbreaks Research (3 papers). W. Tad Archambault is often cited by papers focused on Cardiovascular Function and Risk Factors (5 papers), Heart Failure Treatment and Management (4 papers) and Viral Infections and Outbreaks Research (3 papers). W. Tad Archambault collaborates with scholars based in United States and Canada. W. Tad Archambault's co-authors include Thomas P. Monath, Richard Nichols, Philip Bedford, Nicola Thomas, Robert E. Shope, Manuel Worcel, Linda W. Moore, Richard M. Bittman, Hind T. Hatoum and Lee S. Simon and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and The American Journal of Cardiology.

In The Last Decade

W. Tad Archambault

15 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Tad Archambault United States 10 195 193 120 101 93 16 523
Alessandra Ciccozzi Italy 14 103 0.5× 189 1.0× 58 0.5× 81 0.8× 56 0.6× 61 760
Yvonne Rezvani France 10 283 1.5× 53 0.3× 32 0.3× 54 0.5× 118 1.3× 16 533
Sheila Hickey United States 12 136 0.7× 153 0.8× 94 0.8× 478 4.7× 172 1.8× 16 709
J.G. Hunter United Kingdom 14 89 0.5× 338 1.8× 54 0.5× 178 1.8× 34 0.4× 27 880
Dennis Morrison United States 11 327 1.7× 257 1.3× 46 0.4× 113 1.1× 35 0.4× 15 662
Alison K. Wright United Kingdom 13 66 0.3× 46 0.2× 129 1.1× 134 1.3× 37 0.4× 31 718
Hailong Lin China 16 33 0.2× 108 0.6× 57 0.5× 65 0.6× 26 0.3× 39 613
Julián Solís García del Pozo Spain 13 56 0.3× 93 0.5× 33 0.3× 142 1.4× 51 0.5× 52 564
E. Velasco Brazil 13 38 0.2× 239 1.2× 37 0.3× 184 1.8× 24 0.3× 26 687
Charles Brummitt United States 15 76 0.4× 220 1.1× 21 0.2× 261 2.6× 83 0.9× 28 928

Countries citing papers authored by W. Tad Archambault

Since Specialization
Citations

This map shows the geographic impact of W. Tad Archambault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Tad Archambault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Tad Archambault more than expected).

Fields of papers citing papers by W. Tad Archambault

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Tad Archambault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Tad Archambault. The network helps show where W. Tad Archambault may publish in the future.

Co-authorship network of co-authors of W. Tad Archambault

This figure shows the co-authorship network connecting the top 25 collaborators of W. Tad Archambault. A scholar is included among the top collaborators of W. Tad Archambault based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Tad Archambault. W. Tad Archambault is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Archambault, W. Tad & Dave Ellemberg. (2025). Context Matters: Extra-Personal Factors Underlying Concussion Reporting in University Athletes. Sports. 13(3). 77–77.
2.
Archambault, W. Tad & Dave Ellemberg. (2023). Hard-Headed Decisions: Intrapersonal Factors Underlying Concussion Reporting in University Athletes. SHILAP Revista de lepidopterología. 4(1). 533–542. 2 indexed citations
3.
Gomoll, Andreas H., Bert R. Mandelbaum, Jack Farr, et al.. (2022). An Initial Injection and a Crossover Injection of Amniotic Suspension Allograft Following Failed Treatment with Hyaluronic Acid or Saline Are Equally Effective in the Treatment of Moderate Symptomatic Knee Osteoarthritis Over 12 Months. Arthroscopy The Journal of Arthroscopic and Related Surgery. 39(1). 66–78. 2 indexed citations
4.
Monath, Thomas P., Richard Nichols, Lynda Tussey, et al.. (2022). Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathogens. 18(6). e1010658–e1010658. 18 indexed citations
5.
Bruner, Janet M., David N. Louis, Roger E. McLendon, et al.. (2017). The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. Journal of Neuropathology & Experimental Neurology. 76(3). 189–194. 3 indexed citations
6.
Piña, Ileana L., Peter Carson, JoAnn Lindenfeld, W. Tad Archambault, & Arnold F. Jacobson. (2016). Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from the ADMIRE-HF Trial). The American Journal of Cardiology. 119(3). 434–439. 5 indexed citations
7.
Sabolinski, Michael L., S. William Tam, Susan Ziesche, et al.. (2012). Effect of Fixed-Dose Combined Isosorbide Dinitrate/Hydralazine in Elderly Patients in the African-American Heart Failure Trial. Journal of Cardiac Failure. 18(8). 600–606. 11 indexed citations
8.
9.
Schnitzer, Thomas J., Jean‐Pierre Pelletier, John Ervin, et al.. (2011). Civamide Cream 0.075% in Patients with Osteoarthritis of the Knee: A 12-Week Randomized Controlled Clinical Trial with a Longterm Extension. The Journal of Rheumatology. 39(3). 610–620. 30 indexed citations
10.
Carson, Peter E., S. William Tam, Jalal K. Ghali, et al.. (2009). Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. Journal of Cardiac Failure. 15(10). 835–842. 43 indexed citations
11.
Yancy, Clyde W., Jalal K. Ghali, Virginia Braman, et al.. (2007). Evidence for the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine in Patients With Chronic Heart Failure (the Extension to African-American Heart Failure Trial). The American Journal of Cardiology. 100(4). 684–689. 7 indexed citations
12.
Anand, Inder S., S. William Tam, Thomas S. Rector, et al.. (2006). Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. Journal of the American College of Cardiology. 49(1). 32–39. 47 indexed citations
13.
Monath, Thomas P., Martín S. Cetron, Karen McCarthy, et al.. (2005). Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly. Human Vaccines. 1(5). 207–214. 65 indexed citations
14.
Monath, Thomas P., Gwendolyn A. Myers, W. Tad Archambault, et al.. (2005). Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys. Biologicals. 33(3). 131–144. 43 indexed citations
15.
Monath, Thomas P., Richard Nichols, W. Tad Archambault, et al.. (2002). Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.. American Journal of Tropical Medicine and Hygiene. 66(5). 533–541. 133 indexed citations
16.
Simon, Lee S., et al.. (1996). Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.. PubMed. 28(3). 204–10. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandra Ciccozzi Breakdown of academic impact, for papers by Yvonne Rezvani Breakdown of academic impact, for papers by Sheila Hickey Breakdown of academic impact, for papers by J.G. Hunter Breakdown of academic impact, for papers by Dennis Morrison Breakdown of academic impact, for papers by Alison K. Wright Breakdown of academic impact, for papers by Hailong Lin Breakdown of academic impact, for papers by Julián Solís García del Pozo Breakdown of academic impact, for papers by E. Velasco Breakdown of academic impact, for papers by Charles Brummitt
Rankless by CCL
2026